KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.

Ashley L Lennox, Fei Huang, Mario González-Sales, Ying Wan, Libo Sun, Tymara Berry, Faye Feller, Peter N Morcos

Clin Transl Sci 18(12) e70431

PMID41390988
PMCIDPMC12702135
DOI10.1111/cts.70431
发表日期2025-12-14
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:ROC 图;FIGURE 2:AI 判定为 other。
摘要

摘要

Imetelstat is a first-in-class, 13-mer oligonucleotide telomerase inhibitor approved in the United States and European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with red blood cell (RBC) transfusion-dependent anemia. This post hoc analysis evaluated imetelstat immunogenicity and its association with the pharmacokinetics (PK), efficacy, and safety of imetelstat in patients with LR-MDS from the phase II/III IMerge study (NCT02598661). A validated, semi-quantitative 3-tiered method evaluated anti-drug antibodies (ADAs). Graphical and descriptive analyses evaluated ADA incidence and association with clinical outcomes. Of 166 evaluable patients who received 7.1 mg/kg imetelstat via a 2-h intravenous infusion every 4 weeks, 16.9% developed imetelstat ADAs (median [range] time to onset, 38 weeks [12-109]; ~8 treatment cycles). In ADA-positive patients, peak titer was low (median [range], 30 [10-160]). Evaluations showed no association of ADA positivity with imetelstat PK, nor any negative association with efficacy responses, including ≥ 8-week RBC-transfusion independence (TI), ≥ 24-week RBC-TI, hematologic improvement-erythroid, or duration of RBC-TI response. There was no apparent relationship between the onset of ADAs and loss of RBC-TI. The rates of any-grade or grade ≥ 3 treatment-emergent adverse events (TEAEs) were similar for both ADA groups, with no reported serious TEAEs or TEAEs causing death in ADA-positive patients. Infusion-related TEAEs were more frequent in ADA-positive patients, although the sample size was small. Overall, imetelstat ADAs did not appear to impact imetelstat benefit/risk profile in the LR-MDS population of IMerge, although the analysis is limited by the low incidence of imetelstat ADAs, resulting in a small ADA-positive group.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Effect of immunogenicity on imetelstat pharmacokinetics in patients with LR‐MDS. (a) Observed EOI PK concentrations were grouped by time‐variant ADA (sample‐level) status and nominal dose level for patients with available data ( N = 161 patients, n = 1377 samples). (b) Dose‐normalized EOI PK concentrations were plotted for ADA‐positive patients over time relative to the onset of ADA ( N = 18 ADA‐positive patients with PK data available after seroconversion, n = 261 samples). Time of 0 corresponds to the time of seroconversion. All nominal dose levels were pooled after dose normalization, and lines represent individual patient profiles. The X‐axis was truncated at 105 weeks due to limited data ( N = 1 patient) at late time points. Due to more frequent collection of PK samples than ADA samples, PK samples that lacked an experimentally determined ADA status were imputed to the last available ADA status. The 8.9‐mg/kg dose level was excluded in panels A and B due to limited PK samples ( n = 4 samples). (c) Individual post hoc estimates of baseline CL from popPK model [20] by time‐invariant ADA (patient‐level) status. ADA, anti‐drug antibody; CL, clearance; EOI, end of infusion; LR‐MDS; lower‐risk myelodysplastic syndromes; PK, pharmacokinetics.
非 KM Figure
FIGURE 2FIGURE 2 Effect of immunogenicity on imetelstat efficacy in patients with LR‐MDS. Swimmer plot of RBC‐TI intervals overlaid with positive ADA samples in ≥ 8‐week RBC‐TI responders who were ADA positive. Each row indicates a different patient. Gray shading indicates treatment duration, black arrow indicates treatment ongoing at the last assessment as of the primary analysis cutoff (October 13, 2022), blue shading indicates TI intervals, light green dots indicate time points at which ADAs were detected in blood samples, and red diamonds indicate times of RBC transfusions. ADA, anti‐drug antibody; LR‐MDS; lower‐risk myelodysplastic syndromes; RBC, red blood cell; TI, transfusion independence.
非 KM Figure